about
Circulating miRNAs profiles in Tourette syndrome: molecular data and clinical implications.Increased antistreptococcal antibody titers and anti-basal ganglia antibodies in patients with Tourette syndrome: controlled cross-sectional study.Tourette Syndrome and comorbid ADHD: current pharmacological treatment options.Clinical pharmacology of comorbid attention deficit hyperactivity disorder in Tourette syndrome.Tourette syndrome and comorbid ADHD: causes and consequences.Importance of neuropsychiatric evaluation in children with primary monosymptomatic enuresis.Mandatory electrocardiographic monitoring in young patients treated with psychoactive drugs.Disentangling the effects of Tourette syndrome and attention deficit hyperactivity disorder on cognitive and behavioral phenotypes.Tourette syndrome and comorbid conditions: a spectrum of different severities and complexities.The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.Long term clinical course of Tourette syndrome.Clinical correlates of quality of life in Tourette syndrome.The perception of time in childhood migraine.Long-term neurological outcome of a sextuplet pregnancy.Timing recalibration in childhood Tourette syndrome associated with persistent pimozide treatmentMetabolic Effects of Aripiprazole and Pimozide in Children With Tourette SyndromeOculogyric crisis: a rare extrapyramidal side effect in the treatment of Tourette syndromeCardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndromeADHD and Epilepsy in children with Tourette Syndrome: a triple comorbidity?Re: Importance of neuropsychiatric evaluation in children with primary monosymptomatic enuresisDisentangling Restrictive and Repetitive Behaviors and Social Impairments in Children and Adolescents with Gilles de la Tourette Syndrome and Autism Spectrum Disorder
P50
Q30982356-85C13D8B-310C-43B2-810B-24B6CA8A4051Q34565885-E7913BF1-9370-4454-8BB7-AAB851BE510CQ38087727-10E76715-84A1-43F5-8A96-E79BCB2F43D5Q38167915-7343161C-9E1F-48DD-BF8E-3EDFED4E4D51Q38249952-89B29DF9-5EF9-4027-AD69-76CC81342DE7Q38784685-07253ADD-544E-4BE4-BF77-EDDD5AA21B53Q43898106-940CE899-B7DC-4852-9E19-CF578E18464BQ44808990-8B0B5C3F-642D-4DAF-B4D1-E0EB463EA7F8Q45258952-68B180FA-BDDC-4153-9096-3FBA2960CD95Q46815572-E8F53E87-0978-4482-B171-4E9A54F93948Q48516747-E2DA22D0-5334-4272-A5CA-42F550CB0FC7Q48687353-945BCB66-475B-44B5-8D19-61D84E555A33Q50697557-B3AAC2C9-9C38-420D-A851-BDBE0BE1A449Q51887949-90D5ECAD-6BBC-4940-8C96-6FC1B761A4B2Q59828724-3D0DACB8-189A-4765-8907-589EE701BAF2Q59828884-8A7DEB02-2C77-4E63-931B-0DF2B1A1CE41Q59828895-E62D2AF2-0554-4F22-A07A-052F5F385677Q59828912-4D883564-C071-42FE-96BF-877AE6425D77Q59828998-FF2C65E4-C357-442A-91BD-B2DB46CE6514Q88593020-AD6CA975-7306-4EF3-815C-8A1F9788D150Q95655646-37A58FB3-7D2E-4958-9E25-611B725A5523
P50
description
Forscher
@de
chercheur
@fr
hulumtuese
@sq
investigador
@es
researcher
@en
հետազոտող
@hy
研究者
@zh
name
Mariangela Gulisano
@ast
Mariangela Gulisano
@en
Mariangela Gulisano
@es
Mariangela Gulisano
@nl
type
label
Mariangela Gulisano
@ast
Mariangela Gulisano
@en
Mariangela Gulisano
@es
Mariangela Gulisano
@nl
prefLabel
Mariangela Gulisano
@ast
Mariangela Gulisano
@en
Mariangela Gulisano
@es
Mariangela Gulisano
@nl
P1153
23097929000
P21
P31
P496
0000-0003-4463-098X